Reboot the immune system to avoid transplant rejection New Scientist The first is a drug called alemtuzumab, given intravenously during the transplant surgery. It wipes out the white blood cells, or lymphocytes, that would otherwise attack the new organ. Lymphocyte numbers recover over the following 12 to 18 months, but ... |
